Ethiodized Oil

Summary

Ethiodized Oil (CHEMBL1201458) is an approved unknown; indicated across 5 conditions including neoplasm and hepatocellular carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 5 conditions
• Clinical trials: 41

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201458
Name	Ethiodized Oil
Type	Unknown
Max phase	4

Also known as: Ethiodized oil, Ethiodol, Lipiodol, ETHIODIZED OIL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
thrombotic disease	3	MONDO:0000831	MONDO:0000831
osteoarthritis, knee	1	MONDO:0005416	EFO:0004616

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 41.

Phase distribution

Phase	Trials
PHASE3	12
PHASE2	7
PHASE1	6
Not specified	6
PHASE4	3
PHASE1/PHASE2	3
PHASE2/PHASE3	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01959061	PHASE4	UNKNOWN	Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
NCT02631499	PHASE4	UNKNOWN	Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
NCT05608590	PHASE4	UNKNOWN	What is the Best Moment for Performing an HSG in Women With a Unfulfilled Childwish
NCT00470340	PHASE3	TERMINATED	Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients
NCT00870558	PHASE3	COMPLETED	Iodine I 131 Ethiodized Oil in Preventing Recurrent Cancer in Patients Who Have Undergone Treatment for Liver Cancer
NCT00894946	PHASE3	UNKNOWN	The In Vitro Fertilization - Lipiodol Uterine Bathing Effect Study
NCT01229839	PHASE3	COMPLETED	Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC
NCT01387932	PHASE3	TERMINATED	HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
NCT01861912	PHASE2/PHASE3	UNKNOWN	Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
NCT01966133	PHASE3	UNKNOWN	TACE as an Adjuvant Therapy After Hepatectomy for HCC
NCT02585479	PHASE2/PHASE3	WITHDRAWN	Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
NCT02630108	PHASE3	UNKNOWN	TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma
NCT02755311	PHASE3	UNKNOWN	Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma
NCT02762266	PHASE3	TERMINATED	Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
NCT02971345	PHASE3	UNKNOWN	Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
NCT03192644	PHASE3	UNKNOWN	The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
NCT03542331	PHASE3	UNKNOWN	Endometrial Effects of Lipiodol
NCT04728633	PHASE2	ACTIVE_NOT_RECRUITING	Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
NCT05672108	PHASE2	RECRUITING	Phase II Trial of Lung Chemoemobolization
NCT05842174	PHASE1/PHASE2	RECRUITING	Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
NCT06632717	PHASE2	RECRUITING	Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma
NCT06859164	PHASE2	RECRUITING	Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis
NCT00820053	PHASE2	COMPLETED	A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
NCT01877187	PHASE2	COMPLETED	Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
NCT02638857	PHASE1/PHASE2	UNKNOWN	Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
NCT03727633	PHASE2	TERMINATED	Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion
NCT05435014	PHASE1/PHASE2	SUSPENDED	T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
NCT07395128	PHASE1	RECRUITING	Lateral Plantar Artery Embolization For Plantar Fasciitis
NCT01126463	PHASE1	COMPLETED	188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas
NCT03865563	PHASE1	WITHDRAWN	Selective Transvenous Chemoembolization of Primary Pancreatic Tumors
NCT04200417	PHASE1	COMPLETED	Chemoembolization for Lung Tumors
NCT04733092	PHASE1	COMPLETED	Safety and Efficacy of a Lipiodol Emulsion for the Embolization of Hypervascularizations in Patients With Knee Pain (LipioJoint1)
NCT05490381	PHASE1	WITHDRAWN	Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes
NCT04048317	EARLY_PHASE1	UNKNOWN	Effectiveness of Drug Eluting TACE in Primary HCC
NCT04753918	EARLY_PHASE1	UNKNOWN	Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study
NCT01923064	Not specified	COMPLETED	Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices
NCT02180568	Not specified	COMPLETED	Lipiodol Localization for Ground-glass-opacity Minimal Surgery
NCT03617029	Not specified	UNKNOWN	Localization for Deep Lung Nodules: Microcoil Versus Contrast Injection
NCT04459468	Not specified	COMPLETED	Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC
NCT05021250	Not specified	UNKNOWN	SBRT With DIBH for HCC After TACE and Lipiodol Marking
NCT05291338	Not specified	COMPLETED	Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).